Publications by authors named "Saikrishna Athuluridivakar"
Rigosertib is a styryl benzyl sulfone that inhibits growth of tumor cells and acts as a RAS mimetic by binding to Ras binding domains of RAS effectors. A recent study attributed rigosertib's mechanism of action to microtubule binding. In that study, rigosertib was obtained from a commercial vendor.
View Article and Find Full Text PDFDiscovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).
M V Ramana Reddy Balireddy Akula Stephen C Cosenza Saikrishna Athuluridivakar Muralidhar R Mallireddigari
J Med Chem
February 2014
Article Synopsis
- The success of imatinib for chronic myelogenous leukemia has spurred interest in developing new kinase inhibitors with lower toxicity.
- Researchers analyzed over 150 new cyano pyridopyrimidine compounds to identify trends for creating effective multikinase inhibitors.
- The lead compound, 7x, showed promising results by inducing tumor cell death at low concentrations and effectively inhibiting key kinases involved in cancer progression.